Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Dateline City:
WALTHAM, Mass. & KENILWORTH, N.J.
WALTHAM, Mass. & KENILWORTH, N.J.--(BUSINESS WIRE)--Syndax Pharmaceuticals, Inc., and Merck (NYSE:MRK), known as MSD outside
the United States and Canada, announced today that they have entered
into a clinical trial collaboration to evaluate the safety and efficacy
of combining Syndax’s entinostat, an investigational epigenetic therapy,
with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1
therapy approved in the United States.
Language:
English
Contact:
Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orSyndax Corporate:Bob Goodenow, 781-419-1418Chief Business Officerbgoodenow@syndax.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Lung Cancer | Melanoma | Merck | Skin Cancer | Study